JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler has reiterated a 'Market Outperform' rating on Aquestive Therapeutics (NASDAQ:AQST) and maintained an $8 price target.
September 21, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aquestive Therapeutics' stock rating has been reiterated as 'Market Outperform' by JMP Securities, with a maintained price target of $8.
The reiteration of the 'Market Outperform' rating and the maintained price target by JMP Securities indicates a positive outlook for Aquestive Therapeutics. This could potentially attract investors, leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100